Yilong Wu, MD
Guangdong Provincial People's Hospital · Guangdong General Hospital & Guangdong Academy of Medical Sciences · Guangdong General Hospital, Guangdong Lung Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yilong Wu, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:43 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06930794 · A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-PositiveBeijing Pearl Biotechnology Limited Liability Company · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT06015503 · A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)Avistone Biotechnology Co., Ltd. · active not recruiting · NSCLC (Non-small Cell Lung Cancer) · principal investigator
- Ph3NCT05989542 · A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)Beijing Pearl Biotechnology Limited Liability Company · recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph1NCT05884801 · Phase I Study of QLS1103 in Subjects With Advanced Solid TumorsQilu Pharmaceutical Co., Ltd. · unknown · Advanced Solid Tumor · principal investigator
- Ph1NCT05347628 · Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Avistone Biotechnology Co., Ltd. · unknown · Non-Small-Cell Lung Cancer · principal investigator
- Ph1NCT05025358 · A Study of LP-118 in Patients With Advanced TumorsGuangzhou Lupeng Pharmaceutical Company LTD. · completed · Solid Tumor, Lymphoma, Non-Hodgkin · study chair
- Ph3NCT05009836 · Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCHutchmed · active not recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04580498 · A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLCJiangsu HengRui Medicine Co., Ltd. · unknown · Non-Small-Cell Lung Cancer · principal investigator
- Ph2NCT04258033 · A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)Beijing Pearl Biotechnology Limited Liability Company · completed · Non-small Cell Lung Cancer · principal investigator
- Ph1NCT03995472 · A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced TumorsJiangsu HengRui Medicine Co., Ltd. · completed · Advanced Malignancies · study director
- Ph3NCT03856697 · Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR MutationHangzhou ACEA Pharmaceutical Research Co., Ltd. · unknown · Advanced Non-small Cell Lung Cancer · principal investigator
- Ph3NCT03706690 · A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsAstraZeneca · active not recruiting · Carcinoma, Non-Small-Cell Lung · principal investigator
- Ph2NCT03300115 · Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLCHangzhou ACEA Pharmaceutical Research Co., Ltd. · unknown · Metastatic Non-small Cell Lung Cancer · principal investigator
- Ph1NCT02896231 · First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001Beijing Pearl Biotechnology Limited Liability Company · completed · Non-Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT02330367 · Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLCHangzhou ACEA Pharmaceutical Research Co., Ltd. · unknown · Metastatic Non-small Cell Lung Cancer · principal investigator
- Ph3NCT02151981 · AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerAstraZeneca · completed · Anticancer Treatment · principal investigator
- Ph4NCT00492843 · Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal MetastasisChinese Society of Lung Cancer · terminated · Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:43 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.